Algeta to Present at Forthcoming Life Sciences Investor Conferences
(Thomson Reuters ONE) -
Oslo, Norway, 15 March 2012 - Algeta ASA (OSE: ALGETA), a company focused on the
development of novel targeted cancer therapeutics, announces that members of its
senior management and investor relations team will participate in the following
life sciences investor conferences:
Carnegie Nordic Healthcare Seminar
Date: 21 March 2012
Participants: Andrew Kay (CEO) and Renate Birkeli (IR)
Presentation time: 9:05am CET
Venue: Carnegie Investment Bank AB, Stockholm, Sweden
Kempen & Co Healthcare, Life Sciences Conference 2012
Date: 22 March 2012
Participant: Øystein Soug (CFO)
Venue: Kempen & Co N.V, Amsterdam, the Netherlands
Presentations will be available to download at www.algeta.com following these
events.
###
For further information, please contact
Mike Booth +47 2202 4510
Communications & Corporate Affairs ir(at)algeta.com
International media enquiries: +44 207 638 9571
Mark Swallow mark.swallow(at)citigatedr.co.uk
Citigate Dewe Rogerson
US investor enquiries: +1 646 378 2928
Jessica Lloyd jlloyd(at)troutgroup.com
The Trout Group
About Algeta
Algeta is a company focused on developing novel targeted therapies for patients
with cancer based on its alpha-pharmaceutical platform.
Algeta's lead product Alpharadin (radium-223 chloride) is in development as a
potential new treatment for cancer patients with bone metastases. It is in pre-
registration for castration-resistant prostate cancer (CRPC) patients with bone
metastases, and filings are expected mid 2012 in the USA and Europe; Alpharadin
has Fast Track designation for this indication in the USA.
Alpharadin is also under clinical investigation in breast cancer patients with
bone metastases and in combination with docetaxel chemotherapy in CPRC patients
with bone metastases.
Alpharadin is being developed and will be commercialized, pending approval,
under a global agreement with Bayer Pharma AG.
Algeta is also exploring the potential of Targeted Thorium Conjugates (TTCs),
which are based on conjugating the alpha-emitter thorium-227 to targeting
molecules, as a basis of a future pipeline of tumor-targeting alpha-
pharmaceutical candidates.
The Company is headquartered in Oslo, Norway, and is listed on the Oslo Stock
Exchange (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statements
This news release contains certain forward-looking statements based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Algeta. Such forward-looking
statements reflect our current views and are based on the information currently
available to Algeta. Algeta cannot give any assurance to the correctness of such
statements. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied by these
forward-looking statements. These factors include, among other things, the
ability to successfully commercialize Alpharadin and our other products, risks
in obtaining regulatory approvals for Alpharadin as well as the expected timing
of filings for regulatory approvals, and the other risks and uncertainties
described in our annual report.
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
Press release:
http://hugin.info/134655/R/1593877/501634.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE
[HUG#1593877]
Unternehmensinformation / Kurzprofil:
Datum: 15.03.2012 - 08:00 Uhr
Sprache: Deutsch
News-ID 125090
Anzahl Zeichen: 4765
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 190 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Algeta to Present at Forthcoming Life Sciences Investor Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
